For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
|Videos|March 4, 2021
Find out more about Allergan’s presbyopia drop NDA filing
Potential presbyopia treatment coming
Advertisement
Learn more about the recent new drug application (NDA) Allergan submitted for its investigational eyedrop to treat presbyopia. Optometry Times® Editor in Chief Gretchyn Bailey, NCLC, FAAO, chats with Michael Robinson, MD, vice president, global therapeutic area head of ophthalmology at Allergan, to get details on when ODs could discuss a potential presbyopia treatment with their patients.
Advertisement
Related to this article
Walline, American Academy of Optometry president, shares this year's conference attendance numbers, clinical pearls, and what he hopes to see in 2027.
Thomas Wong, OD, FAAO, details a session he presented alongside Ronald Gentile, MD, FACS, FASRS, at AAOpt 2026.
Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
A single Epioxa epi-on cross-linking treatment sustained a 1.9 D Kmax improvement through three years in keratoconus, with no serious adverse events reported.
Jamie Kuzniar, OD, FAAO, FSLS, discusses a case-based AAOpt 2026 session on scleral lens complications, fitting around cross-linking, and advice for new graduates.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
The screen time question: What to ask and when to look deeper
2
AAOpt 2026: Current controversies in macular hole diagnosis, management
3
AAOpt 2026: Jeffrey Walline, OD, PhD, on his conference takeaways
4
AAOpt 2026: Understanding the gene therapy landscape for retinitis pigmentosa
5